Valeo Pharma Inc (CSE:VPH) (OTCQB:VPHI) (FRA:VP2) has named seasoned executive Frederic Fasano as its president and chief operating officer (COO), a newly-created role, as the company continues its growth story.
Fasano has over 25 years' experience in managing strategic affiliates in Canada, Europe, and Latin America, and before joining Valeo, he was president and CEO of Servier Canada, a fully integrated affiliate of Servier Group - the independent, international and independent pharma group.
READ: Valeo Pharma notes research says Hesperco antioxidant capsules contain compound with potential coronavirus treatment application
"This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years," said Steve Saviuk, who, himself, continues as Valeo's CEO but also becomes vice-chairman.
Richard MacKay remains the chairman of the board.
"I am very excited to join Steve and his team at such a pivotal time in the corporate development of Valeo," Fasano told investors on Monday.
"Valeo is very well positioned to become an anchor Canadian pharma company aiming at bringing innovative treatments to patients.
"Life sciences have been incredibly productive and disruptive in recent times and we at Valeo want to reinvent the way this amazing science is reaching patients."
Quebec-headquartered Valeo commercializes innovative prescription products in Canada with a focus on neurodegenerative diseases, oncology and hospital specialty products.
Contact the author at firstname.lastname@example.org